Elanco Animal Health is evolving from a heavily leveraged consolidator to an innovative competitor in animal health. Its new products like Zenrelia, Credelio Quattro, and Befrena are gaining market share in dermatology and parasiticide segments, challenging rivals like Zoetis. The company is expanding margins and reducing debt, aiming for net leverage below 3.0x by 2027, supported by its Ascend program and strong cash flow. Despite these improvements, Elanco's valuation remains discounted compared to peers, reflecting a more balanced and diversified business model driven by innovation.
Bitcoin surged past the Short-Term Holder Realized Price of $67,000-$69,000 for the first time since May, signaling a potential shift in market momentum. The Long-Term Holder Realized Price remained steady near $49,200, indicating no major sell-off f...
On January 30, 2026, Kevin Warsh was nominated as Federal Reserve Chair, triggering a sharp crypto market sell-off due to expectations of higher interest rates and aggressive balance-sheet cuts. Bitcoin dropped 7% from $84.6k to $78.7k, with $2.4 bil...
Strategy holds 840,447 Bitcoin, about 4% of total supply, valued at $64.86 billion as Bitcoin trades near $77,175, creating an unrealized gain of $1.5 billion over its $63.36 billion acquisition cost. CEO Michael Saylor emphasizes Bitcoin as "digital...
Solana has launched a governance vote on proposal SGP-0002 to double its annual disinflation rate from 15% to 30%, accelerating the reduction of new SOL token issuance. This change could cut the projected six-year SOL supply by 18.9 million tokens, w...
XRP has seen a major rally in South Korea, capturing 32.20% of Upbit's trading volume during a period when the exchange processed about $830 million in just one hour. Upbit's 24-hour turnover reached approximately $3.81 billion, with Bithumb also rep...
